Purdue Pharma expected to forfeit $225m as sentence in criminal opioids case

A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225m to the US justice department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.

The penalty was agreed to in a 2020 pact to resolve federal civil and criminal investigations it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits.

After years of legal twists and turns, the settlement was approved by another judge in November and could take effect on 1 May. It requires members of the Sackler family who own the company to pay up to $7bn to state, local and Native American tribal governments, some individual victims and others.

The forfeiture comes after the Stamford, Connecticut-based Purdue pleaded guilty to three federal criminal charges in November 2020.

Purdue admitted that it did not have an effective program to keep its powerful prescription painkillers from being diverted to the black market, even though it told the US Drug Enforcement Administration (DEA) that it did.

It also admitted that it paid doctors through a speakers program to prescribe the drugs – and paid an electronic medical records company to send doctors information on patients that encouraged more opioid prescriptions.

While Purdue produced only a fraction of the opioid pills that flooded the market in the 2000s, advocates have long seen aggressive sales of OxyContin as one of the touchstones of the crisis. At a 1996 event to rally Purdue’s sales force, Richard Sackler, then a top Purdue executive and later president of the company, called for a “blizzard of prescriptions”.

While Purdue is expected to pay $225m, the government agreed in the plea deal not to collect $5.3bn in criminal forfeitures and fines and $2.8bn in civil liabilities. Instead, portions of that money are considered part of the broader settlement – and the federal government will receive a small slice of that.

The broader settlement calls for members of the Sackler family who own the company to contribute up to $7bn over 15 years. Most of the money is to go to government entities to use to fight the opioid crisis.

It’s among the largest in a series of settlements by drugmakers, wholesalers and pharmacies in recent years – and the only major one that includes payments for some individual victims or their survivors.

Together, the settlements are worth more than $50bn, and most of the money is to be used to address the overdose epidemic.

Under the Purdue deal, members of the Sackler family would be shielded from lawsuits over opioids from those who agree to the payments.

Purdue itself would cease to exist and be replaced by a new company, Knoa Pharma, which would operate for the public benefit and have a board appointed by the states.